先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

未开盘 08-14 16:08:36

12.140

-0.030

-0.25%

最高12.300	最低12.020	成交量410.20万
今开12.230	昨收12.170	日振幅2.30%
总市值311.76亿	流通市值311.76亿	总股本25.68亿
成交额4,978万	换手率0.16%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":12.14,"timestamp":1786694916004,"preClose":12.17,"halted":0,"volume":4102000,"delay":0,"changeRate":-0.0024650780608052062,"floatShares":2568000000,"shares":2568000000,"eps":0.6284201853435761,"marketStatus":"未开盘","change":-0.03,"latestTime":"08-14 16:08:36","open":12.23,"high":12.3,"low":12.02,"amount":49780878,"amplitude":0.023007,"askPrice":12.15,"askSize":21000,"bidPrice":12.13,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.6284201853435761,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":0,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":12.17,"dividendRate":0.017043,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.6928244666540428,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"1196957981","title":"财报前瞻｜先声药业本季度营收预计待披露，机构观点暂不明确","url":"https://stock-news.laohu8.com/highlight/detail?id=1196957981","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196957981?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:33","pubTimestamp":1786581183,"startTime":"0","endTime":"0","summary":"先声药业将在2026年08月20日发布最新季度财报，本文整理上一季度财务要点与主营业务表现，并跟踪市场一致预期与外部观点以供参考。公司现阶段发展前景最大的现有业务集中在“Other Pharmaceutical Business”，上季度该分部收入为58.01亿元，同比增长数据未披露。上季度先声药业营收数据未在工具中披露，但公司毛利率为82.38%，归属于母公司股东的净利润为3.70亿元，净利率为17.86%，调整后每股收益同比数据未披露。财务层面，净利率17.86%的基准为本季度提供比较基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜先声药业本季度营收预计待披露，机构观点暂不明确","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173757928","title":"先声药业（02096）董事会拟于8月20日审议2026年中期业绩及股息派付","url":"https://stock-news.laohu8.com/highlight/detail?id=1173757928","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173757928?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359955,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司（02096）8月10日公告称，公司董事会已排定于2026年8月20日（星期四）召开会议，届时将审议并批准截至2026年6月30日止六个月的未经审计中期业绩，并同步讨论是否派发中期股息。\n公告显示，此次会议由董事长兼执行董事任晋生主持。公司董事会成员包括执行董事唐任宏、万玉山、王熙，以及独立非执行董事宋瑞霖、汪建国、王新华和宋嘉桓。\n根据此前披露，若董事会批准相关业绩报告并决定宣派中期股息，具体方案及金额将另行公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113335908","title":"先声药业7月股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1113335908","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113335908?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:44","pubTimestamp":1785919492,"startTime":"0","endTime":"0","summary":"先声药业（香港交易所股票代码：02096）于2026年8月5日发布截至2026年7月31日止月份的证券变动月报表。报告期内，公司已发行股份总数为2,568,198,618股，库藏股份为0股，股本结构未发生变动。\n根据公告，本月内公司未进行任何新增发行、购回、注销或库藏股交易，股本维持不变。公司报告期末通过受限制股份单位计划可能发行或转让的股份数量为235,201,361股，但在本月并未产生相应新增发行或库藏股份变动。\n公司表示，将继续严格遵守香港联交所《上市规则》及相关法律法规的要求。公告由执行董事及联席公司秘书万玉山签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656322031","title":"【券商聚焦】华泰证券维持先声药业（02096）买入评级 指新品放量及BD常态化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656322031","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656322031?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:18","pubTimestamp":1785748719,"startTime":"0","endTime":"0","summary":"在行业波动背景下，公司超预期的业绩表现展现了新品种的强烈市场需求及高管变动后的效率提升，同时BD的常态化有望带来持续新增量。预计全年内生业务维持中报预告趋势，利润端受益于BD将继续跨越式提升。此外，在SIM0709年初实现BD及SIM0500后续潜在里程碑等带动下，预计公司合作收入将步入常态化，带来持续的收入增量。TCE平台SIM0500的I期数据有望年内读出，TOPOi毒素ADC平台已通过SIM0613和SIM0505的BD出海得到全面验证。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","02096","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655938258","title":"粤十数智、星宇股份、汉得信息递表港交所；和黄医药、先声药业、美图公司发布2026年中期业绩预告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2655938258","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655938258?lang=zh_cn&edition=full","pubTime":"2026-07-31 07:01","pubTimestamp":1785452474,"startTime":"0","endTime":"0","summary":"｜2026年7月31日星期五｜NO.1粤十数智、星宇股份、汉得信息递表港交所据港交所7月29日披露，深圳粤十数智股份有限公司（以下简称粤十数智）、常州星宇车灯股份有限公司（以下简称星宇股份，SH601799）、上海汉得信息技术股份有限公司（以下简称汉得信息，SZ300170）已向港交所主板递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607313827197718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607313827197718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK0188","IE00B5MMRT66.SGD","LU2125910849.SGD","BK1613","00013","BK0264","LU0082770016.SGD","LU0164939612.USD","BK4588","LU2125910500.SGD","BK4007","02096","BK0070","BK0231","BK4531","SG9999006597.SGD","BK1609","BK1588","HCM","BK1618","LU2045819591.USD","IE00B543WZ88.USD","IPOS","01357","BK4585","BK1191","SG9999001093.SGD","300170","BK1612","BK1587","LU0620787316.HKD","601799","BK0065","IE00BPRC5H50.USD","BK1095","LU0082770016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144615695","title":"先声药业预期2026年上半年营收达45.5亿至46.1亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1144615695","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144615695?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:55","pubTimestamp":1785426941,"startTime":"0","endTime":"0","summary":"先声药业（2096.HK）对外发布业绩预告，预计2026年上半年营收将在45.5亿元至46.1亿元人民币之间。相较于去年同期，这一数字预计将录得26.9%至28.6%的显著增幅。上述信息仅为公司初步预测，更多详情请关注后续公告及公司披露文件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655877971","title":"先声药业：预计2026年上半年归母净利润增约34.8%至43.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655877971","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655877971?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:16","pubTimestamp":1785413760,"startTime":"0","endTime":"0","summary":"7月30日，先声药业（02096）发布公告，预计2026年上半年收入将达45.5亿元至46.1亿元，较2025年上半年的35.85亿元增长约26.9%至28.6%。同时，归属于公司权益股东的利润预计为8.1亿元至8.6亿元，相比2025年上半年的6.01亿元增幅约34.8%至43.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303826930212.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303826930212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387678","title":"先声药业(02096.HK)发盈喜，预期上半年收入45.5亿元至46.1亿元 同比增加约26.9%至28.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387678","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655387678?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:02","pubTimestamp":1785409320,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171765207","title":"先声药业预计2026年上半年盈利最高增逾四成 创新药与许可收入驱动业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1171765207","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171765207?lang=zh_cn&edition=full","pubTime":"2026-07-30 19:01","pubTimestamp":1785409264,"startTime":"0","endTime":"0","summary":"2026年7月30日，先声药业集团有限公司发布盈利预告，预计截至2026年6月30日止六个月主要财务指标大幅增长。先声药业预计2026年上半年收入约45.5亿元至46.1亿元，较2025年上半年录得的35.85亿元增加约26.9%至28.6%。扣除以公允价值计量且其变动计入损益的金融资产和联营公司收益、赎回负债利息费用及相关所得税影响后，先声药业预计2026年上半年的经调整归属权益股东的利润约9.5亿元至10.0亿元，较2025年上半年的6.49亿元增长约46.5%至54.2%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176752574","title":"异动解读｜先声药业盘中下跌5.29%，报12.18港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176752574","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176752574?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:23","pubTimestamp":1785381831,"startTime":"0","endTime":"0","summary":"7月30日，先声药业盘中下跌5.29%，报12.18港元/股，成交额1402.59万港元。先声药业所在的制药行业中，板块整体承压，个股中，石药集团跌4.0%，中国生物制药跌5.16%，翰森制药跌2.69%，恒瑞医药跌2.83%，凯莱英跌8.0%。先声药业集团有限公司是一家从事药品的研发、生产和销售的公司，主要产品包括用于中枢神经系统疾病的必存、用于肿瘤疾病的捷百舒和捷佰立、以及用于自身免疫疾病的英太青等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000673","title":"新冠进入中流行水平 医院、药店、药企一线真实情况如何","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000673","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654000673?lang=zh_cn&edition=full","pubTime":"2026-07-28 21:28","pubTimestamp":1785245280,"startTime":"0","endTime":"0","summary":"新冠进入中流行水平 医院、药店、药企一线真实情况如何","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823783420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823783420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0634319403.HKD","09939","02273","09966","KCE","01177","159938","LU2097828714.EUR","LU0348783233.USD","02596","LU1813983027.USD","01276","LU0196878994.USD","BK1521","LU2476274308.USD","06996","BK1219","01548","03692","02162","KURE","02269","02096","LU1880383366.USD","LU0417516571.SGD","LU0856984785.SGD","LU1720050803.USD","HK0000320223.HKD","BK1587","03329","LU2399975544.HKD","06160","09926","01801","02268","03759","LU2039709279.SGD","01530","LU0572944931.SGD","LU2328871848.SGD","01952","01951","06821","01093","06078","HK0000165453.HKD","00013","LU0588546209.SGD","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651253435","title":"港股异动 | 先声药业(02096.HK)盘中涨超6% 近日与美国薛定谔公司达成全球药物发现与开发合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2651253435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651253435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:00","pubTimestamp":1784084414,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651787480","title":"【券商聚焦】交银国际：新版基药目录落地 荣昌、先声、康诺亚关键品种有望迎放量机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2651787480","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651787480?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:14","pubTimestamp":1784078047,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，新版基药目录落地，重点聚焦创新药、慢病药和儿童药：本次新增116个品种均为现行医保目录内药品。据测算，新版基药目录药品占全国公立医疗卫生机构药品配备品种使用总量的71%，其中基层/二级/三级医疗机构占比分别为78%/74%/65%。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985881","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","IE00B5MMRT66.SGD","BK1191","LU1152091168.USD","IE00B543WZ88.USD","BK1147","BK1583","LU0880133367.SGD","LU1152091754.HKD","LU1960683339.HKD","BK1515","KCE","LU1813983027.USD","LU0315179316.USD","02162","IE0008369823.USD","LU1993786604.SGD","LU0067412154.USD","BK1161","03329","LU2328871848.SGD","LU0140636845.USD","LU2039709279.SGD","IE00B031HY20.USD","SG9999004220.SGD","BK1521","HK0000165453.HKD","LU1008478684.HKD","LU1226288253.USD","LU1951186391.HKD","LU0072913022.USD","LU1226287792.SGD","IE0008368742.USD","LU1226287529.USD","LU0326950275.SGD","KURE","IE00BZ08YS42.EUR","09995","LU0501845795.SGD","LU0314109678.HKD","LU1226287875.USD","LU1807302812.USD","LU1328277881.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01093","LU1969619763.USD","LU1226288170.HKD","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650066559","title":"牵手全球AI药物设计龙头薛定谔！先声药业(02096)依托“物理+AI”双技术，重塑创新药管线估值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2650066559","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650066559?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:42","pubTimestamp":1783651368,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年7月10日，先声药业宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。薛定谔公司将凭借其领先的物理学驱动计算平台与专业优势，负责联合药物发现阶段的计算机辅助药物设计与优化。联合药物发现阶段完成后，先声药业将主导后续临床前研究及临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","159992","BK1583","MEDX","BK1191","IBBQ","BK1161","AIPO","02096","AGIX","VTHR","QTOC","06978","ARTY","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135852228","title":"先声药业(02096)自主创新药先必新®纳入2026年版国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1135852228","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135852228?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:05","pubTimestamp":1783598729,"startTime":"0","endTime":"0","summary":"2026年7月9日，先声药业发布自愿公告称，公司自主研发的1类创新药先必新已被正式纳入《国家基本药物目录》，适应症为急性缺血性脑卒中。根据相关管理规定，全国各级公立医疗机构需按要求配备并优先使用目录内药品。目前，先必新已累计惠及超过600万名AIS患者。先声药业表示，此次入选有助于巩固公司在急性脑卒中治疗领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650921572","title":"先声药业(02096)：先必新® (依达拉奉右莰醇注射用浓溶液)纳入2026年版国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650921572","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650921572?lang=zh_cn&edition=full","pubTime":"2026-07-09 20:05","pubTimestamp":1783598727,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年7月9日，集团自主研发的1类创新药先必新® (依达拉奉右莰醇注射用浓溶液)被正式纳入《国家基本药物目录(2026年版)》，用于治疗急性缺血性脑卒中(AIS)。根据基药相关管理规定，全国各级公立医疗机构须按要求配备并优先使用目录内药品。本次入选有利于先必新®突破原有三甲医院局限，加速下沉县域、基层医疗市场，拓宽终端处方场景，叠加现有医保资质，进一步提升药品可及性，稳固集团在急性脑卒中治疗领域的竞争优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业(02096)：先必新® (依达拉奉右莰醇注射用浓溶液)纳入2026年版国家基本药物目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100919489","title":"先声药业更新2026年6月股份变动月报表，股本减少2,749.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1100919489","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100919489?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:49","pubTimestamp":1783327743,"startTime":"0","endTime":"0","summary":"先声药业于2026年7月6日披露2026年6月股份变动月报表，公告显示，截至2026年6月30日，公司已发行股份由2,595,697,618股减少至2,568,198,618股。上述股本变化主要源于公司在2026年1月12日至5月22日期间购回的27,499,000股股份已于2026年6月8日注销，导致本月已发行股份数相应减少。公告指出，先声药业目前无其他股份期权或可换股票据发生变化，购回部分已完成注销，库存股份数量保持为零。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649449116","title":"港股异动 | 先声药业(02096.HK)最高涨近7% 公司强化自身免疫领域产品布局 机构指国内自免市场增长动能强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2649449116","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649449116?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:54","pubTimestamp":1783324478,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648575107","title":"港股直击 | 创新药概念股继续走高，创新药支付改革加速，药企有望持续步入业绩收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2648575107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648575107?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:36","pubTimestamp":1782963369,"startTime":"0","endTime":"0","summary":"7月2日，创新药概念股继续走高，先声药业、三生制药涨超8%；信达生物涨超7%；康方生物涨近7%。消息面上，国家医保局公布2026年医保目录初审结果，共有557个药品通过医保目录初审，54个药品通过商保创新药目录初审，意味着“医保+商保”双目录谈判进入实质推进阶段。与此同时，预申报机制、8年价格保护等新机制同步落地，进一步完善创新药支付体系，为创新药商业化提供更加稳定的政策预期。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462173.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348735423.USD","LU2399975544.HKD","LU2476274308.USD","BK1583","BK1574","LU2778985437.USD","IE00B5MMRT66.SGD","BK1589","LU1794554557.SGD","BK1161","LU0348767384.USD","LU2097828631.EUR","LU0417516738.SGD","LU0348827113.USD","01801","LU0348825331.USD","BK1191","01530","BK4585","LU2097828805.USD","LU2242644610.SGD","VXUS","LU0348783233.USD","LU0455707207.USD","LU2097828557.USD","LU0634319403.HKD","LU2328871848.SGD","LU1720050803.USD","HK0000165453.HKD","LU2097828714.EUR","LU0540923850.HKD","LU0502904849.HKD","LU2476274720.SGD","LU1961090484.USD","BK4588","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU1969619763.USD","LU0561508036.HKD","09926","LU2488822045.USD","159992","02096","06978","LU0417516902.SGD","LU0417516571.SGD","BK1593","LU2097828474.EUR","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.0654},{"period":"3month","weight":0.0895},{"period":"6month","weight":-0.0382},{"period":"1year","weight":-0.009},{"period":"ytd","weight":0.0357}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.09318},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070754},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014037},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105952},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032044},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001102},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.045589},{"month":9,"riseRate":0.4,"avgChangeRate":-0.032404},{"month":10,"riseRate":0.8,"avgChangeRate":0.108743},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044296},{"month":12,"riseRate":0.5,"avgChangeRate":0.000556}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}